Molecular analysis of a CD19-negative diffuse large B-cell lymphoma

Haematologica. 2019 Mar;104(3):e114-e116. doi: 10.3324/haematol.2018.203521. Epub 2018 Dec 13.

Authors

Affiliations

¹ Cancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Equipe labellisée Ligue Contre le Cancer, Université de Lyon.
² Hospices Civils de Lyon, Groupement Hospitalier Sud, Service d'hé-matologie biologique, Pierre-Bénite.
³ Centre Hospitalier Ardèche Nord, Service de Médecine Interne, Annonay.
⁴ Hospices Civils de Lyon, Groupement Hospitalier Sud, Service d'anatomopathologie, Pierre-Bénite, France.
⁵ Cancer Research Center of Lyon, INSERM U1052 UMR CNRS 5286, Equipe labellisée Ligue Contre le Cancer, Université de Lyon pierre.sujobert@chu-lyon.fr.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antigens, CD19 / genetics
Antigens, CD19 / metabolism*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers
Biopsy
Bone Marrow / pathology
Cyclophosphamide / adverse effects
Cyclophosphamide / therapeutic use
DNA Mutational Analysis
Disease Susceptibility
Doxorubicin / adverse effects
Doxorubicin / therapeutic use
Female
Humans
Immunohistochemistry
Immunophenotyping
Lymphoma, Large B-Cell, Diffuse / diagnosis*
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / etiology
Lymphoma, Large B-Cell, Diffuse / metabolism*
Molecular Diagnostic Techniques
Mutation
Prednisone / adverse effects
Prednisone / therapeutic use
Rituximab / adverse effects
Rituximab / therapeutic use
Treatment Outcome
Vincristine / adverse effects
Vincristine / therapeutic use

Substances

Antigens, CD19
Biomarkers
CD19 molecule, human
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone